REATA PHARMACEUTICALS INC-A (RETA)

US75615P1030 - Common Stock

172.36  +0.04 (+0.02%)

After market: 172.4 +0.04 (+0.02%)

REATA PHARMACEUTICALS INC-A

NASDAQ:RETA (9/25/2023, 7:12:09 PM)

After market: 172.4 +0.04 (+0.02%)

172.36

+0.04 (+0.02%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/bmo
Ins Owners1.69%
Inst Owners94.14%
Market Cap5.79B
Shares33.59M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts53.33
IPO05-26 2016-05-26
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RETA Daily chart

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The firm's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. The company is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.

Company Info

REATA PHARMACEUTICALS INC-A

5320 Legacy Dr

Plano TEXAS 75024

P: 19728652219.0

CEO: J. Warren Huff

Employees: 321

Website: https://www.reatapharma.com/

RETA News

News Imagea day ago - Biogen Inc.Biogen Completes Acquisition of Reata Pharmaceuticals
News Image6 days ago - Seeking AlphaReta shareholders clear buyout deal with Biogen (NASDAQ:RETA)

Reata Pharmaceuticals (RETA) said that its shareholders approved its previously disclosed acquisition by Biogen (BIIB) at a special meeting on Thursday. Read more here.

News Image6 days ago - Reata Pharmaceuticals, Inc.Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
News Image15 days ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, TRHC, VRTV, CTG

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image15 days ago - Market News VideoFirst Week of January 2026 Options Trading For Reata Pharmaceuticals (RETA)
News Image16 days ago - Market News VideoNotable Monday Option Activity: SPLK, FUBO, RETA

RETA Twits

Here you can normally see the latest stock twits on RETA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example